On August 2, Gelunhui reported that Tianjin Lisheng Pharmaceutical (002393.SZ) announced that its subsidiary, Tianjin Zhongyao Pharmaceutical Co., Ltd. (referred to as "Zhongyao Pharmaceutical") has received a notice from its joint venture company Tasly Biomedical Industry Group Co., Ltd. (hereinafter referred to as "Tasly Group"), stating that the latter is planning to transfer the shares of its holding subsidiary Tasly Pharmaceutical Group Co., Ltd. (Stock Code: 600535, Stock Abbreviation: Tasly), which may result in a change in the control of Tasly Pharmaceutical Group Co., Ltd.
The subsidiary of the company, Zhongyao Pharmaceutical, holds a 12.15% equity stake in Tasly Group, which is accounted for as a non-trading equity instrument investment measured at fair value with changes in its fair value recognized in other comprehensive income.
